Oppenheimer & Co. Inc. Buys 24,964 Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Oppenheimer & Co. Inc. grew its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 24.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 129,195 shares of the biotechnology company's stock after purchasing an additional 24,964 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.28% of Capricor Therapeutics worth $1,226,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after purchasing an additional 700,243 shares during the period. Farallon Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $31,056,000. Geode Capital Management LLC lifted its stake in shares of Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock valued at $12,139,000 after purchasing an additional 241,279 shares during the period. Altium Capital Management LLC lifted its stake in shares of Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after purchasing an additional 429,000 shares during the period. Finally, Woodline Partners LP acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at $8,693,000. Institutional investors and hedge funds own 21.68% of the company's stock.

Wall Street Analysts Forecast Growth

CAPR has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, June 24th. Jones Trading lowered their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday. Oppenheimer lowered their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating for the company in a research report on Monday, June 23rd. Roth Capital restated a "buy" rating and issued a $31.00 price objective on shares of Capricor Therapeutics in a research report on Tuesday, June 17th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $33.75.

Capricor Therapeutics Stock Up 9.5%

NASDAQ:CAPR opened at $11.15 on Friday. The stock's 50 day moving average price is $10.88 and its two-hundred day moving average price is $12.35. The firm has a market capitalization of $509.33 million, a price-to-earnings ratio of -7.85 and a beta of 0.84. Capricor Therapeutics, Inc. has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the business posted ($0.31) EPS. Equities research analysts expect that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.